Larkberget

Larkberget ROA

The Return on Assets (ROA) of Larkberget (LARK.ST) as of Oct 21, 2026 is -21.79 %. In the previous year, Return on Assets (ROA) was -59.14 % — a change of -63.17% (higher).

ROA

-21.79 %

YoY

-63.17%

Last updated:

In 2025, Larkberget's return on assets (ROA) was -21.79 %, a -63.17% increase from the -59.14 % ROA in the previous year.

The Larkberget ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-37.44 SEK
Jan 1, 2019
-40.71 SEK
Jan 1, 2020
-38.75 SEK
Jan 1, 2021
12.61 SEK
Jan 1, 2022
-3.89 SEK
Jan 1, 2023
-29.57 SEK
Jan 1, 2024
-59.14 SEK
Jan 1, 2025
-21.79 SEK
The Larkberget ROA history
YEARROAYoY
-21.79 %-63.17%
-59.14 %+100.01%
-29.57 %+659.88%
-3.89 %-130.85%
12.61 %-132.55%
-38.75 %-4.81%
-40.71 %+8.75%
-37.44 %-65.99%
-110.06 %-37.91%
-177.25 %+200.23%
-59.04 %+283.80%
-15.38 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Larkberget Stock analysis

What does Larkberget do? CombiGene AB specializes in developing treatments for neurological disorders using gene therapy vectors. The company's platform delivers combinations of transgenes encoding neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors. CombiGene focuses on an epilepsy treatment utilizing an adeno-associated virus (AAV) vector carrying transgenes for NPY and its Y2 receptor. The firm targets neurological and psychiatric diseases in humans and animals through its gene therapy approach. CombiGene AB's products are developed for the treatment of epilepsy and other neurological conditions. The company's platform is designed to deliver multiple therapeutic elements simultaneously via gene therapy vectors. The firm's focus on AAV vectors carrying specific transgenes reflects its strategy to address complex neurological disorders with targeted gene-based therapies. The company's target segments include patients with neurological and psychiatric diseases requiring innovative treatment options. CombiGene AB's development pipeline centers on epilepsy treatment using NPY and Y2 receptor transgenes. The firm's approach involves creating therapies that combine multiple biological components to address disease mechanisms more effectively. Larkberget is one of the most popular companies on Eulerpool.

ROA Details

Understanding Larkberget's Return on Assets (ROA)

Larkberget's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Larkberget's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Larkberget's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Larkberget’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Larkberget stock

Return on Assets (ROA) of Larkberget is -21.79 % in 2025.

Return on Assets (ROA) of Larkberget changed from -59.14 % to -21.79 %, representing a -63.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Larkberget since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Larkberget with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Larkberget

All Key Metrics — Larkberget